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Circulating RNAs extracted from liquid biopsies represent a promising
source of cancer- and therapy-related biomarkers. We screened whole blood
from patients with metastatic castration-resistant prostate cancer (mCRPC)
following their first-line treatment with abiraterone acetate and prednisone
(AA-P) to identify circulating RNAs that may correlate with progression-free
survival (PFS). In a prospective multicenter observational study, 53 patients
with mCRPC were included after they started first-line AA-P treatment.
Blood was drawn at baseline, 1, 3, and 6 months after treatment initiation.
The levels of predefined circulating RNAs earlier identified as being upregu-
lated in patients with mCRPC (e.g., microRNAs, long noncoding RNAs,
and mRNAs), were analyzed. Uni- and multivariable Cox regression and
Kaplan–Meier analyses were used to analyze the prognostic value of the vari-
ous circulating RNAs for PFS along treatment. Detectable levels of kallik-
rein-related peptidase 3 (KLK3) mRNA at baseline were demonstrated to be
an independent prognostic marker for PFS (201 vs 501 days, P = 0.00054).
Three months after AA-P treatment initiation, KLK3 could not be detected
in the blood of responding patients, but was still detectable in 56% of the
patients with early progression. Our study confirmed that KLK3 mRNA
detection in whole blood is an independent prognostic marker in mCRPC
patients receiving AA-P treatment. Furthermore, the levels of circulating
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KLK3 mRNA in patients receiving AA-P treatment might reflect treatment
response or early signs of progression.
1. Introduction
Prostate cancer (PCa) is the second most common can-
cer in men worldwide [1]. It presents with a wide range
of disease stages, from localized PCa to lethal meta-
static castration-resistant prostate cancer (mCRPC).
The therapeutic landscape for patients with mCRPC is
rapidly evolving, with several new therapies improving
overall survival (OS). Abiraterone acetate and pred-
nisone (AA-P) is one of these therapies that has been
proven to prolong OS in patients with mCRPC [2,3].
However, suboptimal response [de novo resistance or
shorter progression-free survival (PFS)] has been
observed in a subset of patients and eventually all
patients develop therapy resistance. To improve out-
come and cost-effectiveness, it is important to select
patients for treatment with AA-P that will benefit
most.
Liquid biopsies are a promising source for biomar-
ker analysis. Besides circulating tumor DNA and cir-
culating tumor cells (CTC), liquid biopsies also
contain circulating RNAs, protein-coding mRNAs,
and noncoding RNAs (ncRNAs), such as microRNAs
(miRNAs) and long noncoding RNAs (lncRNAs), all
of which can be released by the tumor into the circula-
tion [4]. Liquid biopsies are minimally invasive, and
therefore, longitudinal sample collection and biomar-
ker analysis are feasible. Furthermore, with liquid
biopsies it is possible to identify tumor heterogeneity
in a single biopsy [5].
Detection of cancer-specific mRNAs has the poten-
tial to characterize the tumor and determine tumor
burden in blood. The prostate-specific kallikrein-related
peptidase 3 (KLK3) mRNA, which codes for prostate-
specific antigen (PSA), is a clinically validated diagnos-
tic marker used in urine-based tests [6]. Furthermore,
the predictive value of KLK3 mRNA decreases in
patients with advanced PCa treated with docetaxel has
been explored [7]. Danila et al. [8] have developed and
validated a droplet digital polymerase chain reaction
(ddPCR)-based assay to detect gene transcripts
(KLK2, KLK3, HOXB13, GRHL2, and FOXA1) that
are highly expressed in prostate tissue and peripheral
blood from patients with mCRPC. The AdnaTest is
an assay that detects KLK3, PSMA, and EGFR tran-
scripts in CTCs captured on magnetic beads [9]. Both
the AdnaTest and ddPCR are considered positive if at
least one of the transcripts is detected. In a clinical val-
idation study, Danila et al. [9] showed that KLK3
detection was the primary marker for positive AdnaT-
est and ddPCR test results. Therefore, they suggested
to remove the less-useful transcripts from those tests
and only measure KLK3. However, these results have
not been confirmed in a prospective clinical trial yet.
MiRNAs are short (~ 21 nucleotide) single-
stranded RNAs that are able to drive tumor initia-
tion and progression by controlling the expression of
oncogenes and tumor suppressor genes [10]. Clinical
studies showed that upregulation of miR-21, miR-
141, miR-200a, miR-200c, miR-375, and miR-3687
are related to shorter PFS or OS in patients with
CRPC [11–13].
LncRNAs are lncRNA transcripts with a length of
more than 200 nucleotides [14]. An aberrant expression
of many lncRNAs has been associated with PCa [15].
Prostate cancer-associated 3 (PCA3) is currently used
in PCa diagnostic urine tests [16,17]. Furthermore, the
association of PCA3 levels with treatment outcome
was explored in a small cohort of patients treated with
docetaxel [7]. Another lncRNA which has been shown
to be upregulated in PCa tissue compared with benign
tissue is SWI/SNG complex antagonist associated with
prostate cancer 1 (SCHLAP1) [18,19]. Beside these,
many other lncRNAs are being explored but the prog-
nostic or predictive value for patients with mCRPC is
yet unclear.
Although preclinical work revealed many biomark-
ers of potential use, the number of biomarkers that are
translated to the clinical practice is very disappointing.
In the biomarker landscape, many researchers are dis-
covering new biomarkers, but without further valida-
tion their clinical usefulness is limited [20]. The
ultimate goal is to implement biomarkers in clinical
practice, and therefore, prospective validation is
important and crucial. For AA-P, only androgen
receptor splice variant 7 (AR-V7) is used as a predic-
tive biomarker. Detection of AR-V7 in CTCs is associ-
ated with abiraterone acetate and enzalutamide
resistance [21,22]. Though, the detection and thereby
use of AR-V7 as a predictive marker appears to be
treatment line specific, since AR-V7 is only detectable
in 3% of first-line patients vs 18–31% in second line
or higher and is therefore only useful to guide treat-
ment in more advanced mCRPC patients [23].
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Therefore, it also seems to be very important to study
the value of biomarkers in a well-defined stage of dis-
ease.
A prognostic index model for chemotherapy-na€ıve
patients treated with AA-P has been described, includ-
ing the following clinical parameters: presence of
lymph node metastasis, lactate dehydrogenase (LDH)
> upper limits of laboratory normal (ULN), ≥ 10 bone
metastasis, hemoglobin (Hb) ≤ lower limits of labora-
tory normal (LLN), and PSA > 39.5 ngmL1 [24].
However, the additional value of novel biomarkers
and drug exposure in this model has not been well-
studied. Abiraterone shows substantial interpatient
variability in drug exposure [25]. For abiraterone, a
minimum concentration (Ctrough) of 8.4 ngmL1 is
suggested as a threshold for efficacy [26,27]. Subopti-
mal exposure, defined as a Ctrough below 8.4 ngmL1,
has never been incorporated in prediction models
before. Therefore, a prospective, observational multi-
center study was conducted to explore the value of
(pre)clinically identified promising circulating RNAs as
prognostic biomarkers as well as the influence of abi-
raterone exposure on PFS in first-line mCRPC patients
(ClinicalTrials.gov ID: NCT02426333).
2. Materials and methods
2.1. Study design
This prospective, observational, multicenter study was
conducted in five hospitals in the Netherlands. All
patients with mCRPC starting first-line AA-P treat-
ment, according to the drug label, were eligible.
Patients were allowed to be pretreated with upfront
docetaxel according to CHAARTED/STAMPEDE
protocols in a hormone-sensitive prostate cancer set-
ting. Comedication that affected abiraterone pharma-
cokinetics was not allowed (e.g., potent CYP3A4
inhibitors and inducers). Patients were replaced if they
stopped treatment or had dose reductions before the
second visit (1 month after start). The study was con-
ducted in accordance with Good Clinical Practice and
the Declaration of Helsinki and approved by our
Investigational Review board. Written informed con-
sent was obtained from all patients before entering the
study.
To identify biomarkers that are upregulated in PCa
patients, blood from healthy individuals was used as
control. Thirty healthy individuals (10 men < 35 years,
10 men between 55 and 70 years, and 10 women [no
age restriction]), gave written informed consent for the
use of an aliquot of their donated blood as control.
2.2. Assessments
During the study period of 6 months, patients had to
visit the hospital at baseline, 1, 3, and 6 months after
inclusion for physical examinations, laboratory tests,
and blood collection. For biomarker analysis, blood
was collected in PAXgene Blood RNA Tubes (PreAn-
alytiX; Qiagen/BD-company, Hombrechtikon, Switzer-
land) at each visit. Plasma was collected in EDTA
tubes at 1, 3, and 6 months for measuring abiraterone
concentrations. Patients were instructed to take their
abiraterone acetate (1000 mg once daily, combined
with 10 mg of prednisolone) in the morning 1 h before
breakfast. At the day of pharmacokinetic assessment,
AA-P was taken after the first blood collection for
measuring the abiraterone trough level. Patients filled
out a diary to check for drug adherence and side
effects. Their diary and concomitant medication were
checked during every visit.
Imaging was performed at baseline, 3, and 6 months
after start of therapy. Tumor response was assessed by
the treating physician and by an independent investiga-
tor during the study period, according to Response
Evaluation Criteria in Solid Tumors (RECIST) v1.1
criteria. Progression during the study was defined
according to the Prostate Cancer Working Group 3
(PCWG3) criteria. For patients not progressing before
the final study visit at 6 months, progression thereafter
was assessed by the treating physician. Survival data
were collected from patients’ medical record by the
research nurse. Progression could be radiographic, bio-
chemical, or clinically. Quality check of data-entry was
performed by an independent monitor.
2.3. Biomarker analysis
2.3.1. RNA isolation from whole blood
The following biomarkers were selected for analyses
based on previous data; mRNAs: AR, AR-V7, and
KLK3; miRNAs: miR-21, miR-141, miR-200a, miR-
200c, miR-375, and miR-3687; lncRNAs:
AC012531.25, NAALADL2-AS2, PCA3, SCHLAP1,
and SNHG3 [21,22,11,12,7,13,18,28,29].
Total RNA was isolated from whole blood collected
in PAXgene Blood RNA Tubes (blood volume 2.5 mL
with 6.9 mL additive), using the PAXgene Blood
miRNA and PAXgene Blood RNA kits (PreAnalytiX;
Qiagen/BD-company), according to the manufacturer’s
instructions. The biological source of total RNA is
both cells and exosomes. In this study, we included
only first-line patients, and hence, the number of CTCs
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is expected to be very low, and therefore, the isolated
RNA is mainly from blood cells and tumor-derived
exosomes and only minimally from CTCs. (Cell free
RNA is very unstable and susceptible to degradation,
and will therefore not be detected.) PAXgene blood
RNA tubes (Qiagen) are specifically developed and
validated to isolate RNA from blood specimens. PAX-
gene tubes allow instant preservation of RNA, and the
quality of RNA extracted using these tubes has been
thoroughly investigated [30].
For miRNA analysis, each blood sample was first
spiked with 2.0 fmoles of each C. elegans miR-39 and
miR-238 (Table S1). RNA was eluted from the col-
umns using 50–80 µL elution buffer. The samples were
stored in nonstick RNase-free tubes at 20 °C until
further use. Total RNA quantification was performed
on a Qubit 3.0 Fluorometer using the Qubit RNA BR
Assay Kit (Thermo Fisher Scientific, Waltham, MA,
USA). RNA quality was assessed on an Agilent 2100
Bioanalyzer Instrument using RNA Nano Chips (Agi-
lent, Santa Clara, CA, USA). The median RNA integ-
rity number value was 8.5 (range 5.4–9.9).
2.4. Reverse transcriptase and real-time PCR
analysis
Gene expression analysis was performed by relative
quantification of mRNA levels and levels of the PCA3
lncRNA using fluorescence-based quantitative real-
time PCR assays, which were developed according to
the MIQE guidelines [31]. Total RNA (extracted with
the PAXgene Blood RNA Kit) was used for cDNA
synthesis. RNA was first treated with DNaseI, and
then, cDNA was synthesized, essentially as described
by Dijkstra et al. [32]. RNA levels were determined by
real-time PCR using gene-specific primers and hydroly-
sis probes (Tables S2,S3) and a LightCycler LC480
Instrument (Roche, Basel, Switzerland). Crossing point
(Cp) values were calculated using the 2nd derivative
method and the LightCycler LC480 Software (Roche).
Copy numbers were calculated using calibration curves
with a wide linear dynamic range, generated by serial
dilutions (10–1 000 000 copies) of linearized plasmids
(pCR2.1-TOPO vector-based) containing the target
gene sequences.
MiRNA levels were measured using a stem-loop
reverse transcriptase (SL-RT) PCR, adapted from
Chen et al. [33]. SL-RT was performed, using 2.0 µL
of total RNA (extracted with the PAXgene Blood
miRNA Kit) and 0.375 pmoles miRNA-specific SL-
RT primer (Table S4). MiRNA levels were corrected
for differences in blood volume. For lncRNA analysis,
250 ng total RNA (extracted with the PAXgene Blood
RNA Kit) was used for cDNA synthesis. RNA was
first treated with DNaseI, and then, random-primed
cDNA was synthesized using SuperScript II Reverse
Transcriptase (Invitrogen, Carlsbad, CA, USA). RNA
levels were determined by SYBR Green real-time PCR
using a LightCycler LC480 Instrument (Roche). Rela-
tive RNA levels were calculated using the weighted
average of the C. elegans spiked-in miRNAs (for miR-
NAs) or GAPDH (for lncRNAs) levels for normaliza-
tion. Primer sequences are listed in Tables S2,S5; RT
reaction conditions and PCR cycle conditions are
listed in Tables S6,S7.
2.4.1. Biomarker analysis in healthy controls
MiRNAs and the AR mRNAs were measured in 30
healthy individuals. LncRNA levels were measured in
10 age-matched men. Levels of KLK3 mRNA and
PCA3 lncRNA were not measured in healthy controls,
since previous work revealed that these transcripts are
only present in CRPC patients compared with healthy
individuals [7]. Average Cp values in healthy controls
were calculated and used as a reference.
2.4.2. Biomarker analysis in patients
RT–PCR was performed twice for each sample to test
for reproducibility. The RNA levels of AR, AR-V7,
KLK3, and PCA3 were analyzed by using a calibration
curve. Biomarkers were classified negative if one or both
samples were below the lowest point of the calibration
curve. For the miRNAs and lncRNAs (except PCA3),
no calibration curve was used and the relative expres-
sion was calculated. For miRNAs, we used the follow-
ing algorithm: If the mean Cp value of the replicates is
> 37 and/or delta Cp of the replicates is > 1.0, a Cp
value of 45 was used for analysis. For lncRNAs, the fol-
lowing algorithm was used: If the mean Cp value of the
replicates is > 38 and/or delta Cp of the replicates is
> 1.5, a Cp value of 45 was used for analysis. The rela-
tive RNA expression levels in mCRPC patients com-
pared with healthy controls (using the DDCt method)
were calculated. If mean baseline levels of a biomarker
in patients were more than twofold higher compared
with healthy controls, they were included for survival
analysis. All biomarkers that did not meet this criterion
were excluded for further analysis.
2.4.3. Follow-up of biomarker levels related to
treatment response
To investigate whether there is a relation between bio-
marker levels over time and treatment response,
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biomarker levels were measured longitudinally. Only
the biomarkers showing a relation with PFS in the
univariable analyses (P-value ≤ 0.1) were selected for
longitudinal analyses. RNA expression levels of these
biomarkers are visualized over time for patients with
early progression (progression within 6 months) com-
pared to patients with stable disease or responders (no
progression within 6 months). Patients who stopped
treatment due to toxicity were excluded from longitu-
dinal analyses.
2.5. Pharmacokinetic assessment
The abiraterone concentration was measured by a vali-
dated liquid chromatography-tandem mass spectrome-
try method [34]. Abiraterone plasma concentrations
were calculated at exactly 24 h after ingestions. For
calculating the trough levels, Bayesian estimation was
used based on a population pharmacokinetic model
described by Stuyckens et al. [35]. The population
pharmacokinetic parameters were re-estimated based
on the data collected in our study. The average abi-
raterone calculated trough levels at 1, 3, and 6 months
per patient were used for further analysis.
2.6. Statistics
The primary endpoint was a difference in PFS on first-
line AA-P treatment explained by biomarker expres-
sion and/or drug exposure. Univariable Cox regression
was used to identify whether biomarkers and drug
exposure were related to PFS by estimating hazard
ratios (HR) and corresponding 95% confidence inter-
vals (CI). Cutoff values for biomarkers were calculated
using the maximally selected rank statistics. The cutoff
value used for the effect of abiraterone exposure on
survival was the earlier identified abiraterone trough
concentration of 8.4 ngmL1 [26,27]. Pretreatment
according to CHAARTED / STAMPEDE protocols
and presence of visceral metastasis were added in uni-
variable analysis too.
Biomarkers and abiraterone exposure were included
in the multivariable model and Kaplan–Meier (KM)
analysis if the P-value was ≤ 0.1 in the univariable
Cox regression. Based on a previous defined prognos-
tic index model for PFS in chemotherapy-na€ıve
mCRPC patients treated with AA-P, the following
covariables were added to the multivariable model
regardless of the univariable outcome: presence of
lymph node metastasis, LDH > ULN, ≥ 10 bone
metastasis, Hb ≤ LLN, and PSA > 39.5 ngmL1 [24].
Missing covariables were kept missing. Since this study
was an exploratory study, no corrections for multiple
testing were done. KM curves and log-rank tests were
used to compare differences in PFS between groups
with a biomarker expression or drug exposure above
and below the cutoff. Statistical significance was set at




From January 2016 to October 2018, 57 patients
entered the study. Four patients were excluded [two
patients stopped directly, one patient stopped before
the second visit, and one patient did not meet with the
inclusion criteria (treated with AA-P as second-line
treatment)]. In total, 53 patients were included for
analysis. At the time of analysis, 74% of the patients
(N = 39) showed progression, with a median PFS of
11 months (range 2–30 months) and 28% of the
patients (N = 15) died. Radiologic progression was
reported for 30 patients, biochemical progression only
was reported for six patients, one patient stopped due
to clinical progression and two patients died due to
progressive disease. Three patients stopped AA-P ther-
apy because of toxicity. These patients were censored
for survival analysis. The median follow-up time for
patients still on AA-P therapy was 18 months (range
12–26 months). Baseline characteristics are summa-
rized in Table 1.
3.2. Expression levels of circulating RNAs
Expression levels of miRNA and AR in healthy indi-
viduals were not different between the three groups of
healthy controls, and therefore, their blood RNA val-
ues were pooled. AR-V7 was not detectable in healthy
controls. All individual biomarker expression levels in
healthy controls are listed in Table S8.
For miR-375, miR-3687, and NAALADL2-AS2, the
mean relative circulating RNA levels were more than
twofold higher in patients compared with healthy con-
trols and were therefore included as putative prognos-
tic biomarkers in the survival analyses. AR-V7 could
be detected in 6 patients at baseline and KLK3 was
detectable in 17 patients at baseline. Both were
included for survival analysis. For miR-21, miR-141,
miR-200a, miR-200c, AR, AC012531.25, and SNHG3
the mean baseline levels were less than twofold higher
compared with healthy controls, and therefore, no sur-
vival analysis was performed for these biomarkers.
PCA3 was detectable in only two patients, and
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SCHLAP1 was not detectable in any patient and
therefore excluded for survival analysis. The mean bio-
marker expression levels of all patients per timepoint
are shown in Table 2.
3.3. Progression-free survival analysis
3.3.1. Univariable and multivariable Cox regression
AR-V7, KLK3, miR-375, miR-3687, NAALADL2-AS2,
drug exposure, pretreatment according to
CHAARTED / STAMPEDE protocols and presence
of visceral metastasis were included in univariable Cox
regression (Table 3). KLK3 and AR-V7 were only
detectable in a subset of patients, and therefore, the
cutoff was set at detectable yes or no. The cutoff val-
ues for miR-375, miR-3687, and NAALADL2-AS2 cal-
culated with maximally selected rank statistics were
2.16, 0.29, and 3.66 (relative to healthy controls),
respectively.
High levels of miR-375 and detectable KLK3
mRNA levels were related to PFS (HR 1.78; 95% CI
0.93–3.41; P = 0.08 and HR 3.16; 95% CI 1.59–6.27;
P =< 0.0001). All other parameters were not related to
PFS (in univariable analysis) and therefore not
included in multivariable Cox regression analysis. In a
multivariable Cox regression model, detectable KLK3
mRNA levels and presence of lymph node metastasis
were both independent predictors of shorter PFS (HR
Table 1. Baseline characteristics. ALP, alkaline phosphatase;
DHEAS, dehydroepiandrosterone sulfate. Data are presented as
median (Q1–Q3) for continuous data or N (%) for categorical data.
Patient characteristics at baseline Total N = 53
Age at baseline (years) 71 (65–78)
Weight at baseline (kg) 86 (80–93)
Hb (mM) 7.9 (7.4–8.4)
LDH (UL1) 230 (206–264)
ALP (UL1) 85 (71–125)
Albumin (gdL1) 4.1 (3.7–4.4)
PSA (ngmL1) 39 (23–130)
PSA doubling time (months) 3.3 (2.3–6.1)
DHEAS (µM) 1.6 (0.9–2.5)
N (%)
Gleason score at diagnosis
≤ 7 13 (24.5)












Anti-androgen pretreatment 38 (71.7)
Otherb 1 (1.9)
> 10 metastases at baseline 21 (39.6)
Spread of disease
Lymph only 5 (9.4)
Bone only 14 (26.4)
Both bone and lymph 24 (45.3)
Visceral + lymph node/bone 9 (17.0)
a



























AR-V7b 6 (11.32) 2 (3.77) 1 (1.89) 2 (3.77)














































































SCHLAP1a ND ND ND ND
a
Relative expression levels compared with healthy controls, mean
(range).
b
Number of detectable samples (≥ the lowest point of the calibra-
tion curve), N (%).
c
For the lncRNAs only samples of 52 patients were available at
baseline.
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5.07; 95% CI 1.81–14.18; P = 0.0020 and HR 2.57;
95% CI 1.20–5.50, P = 0.0149 respectively; Table 3).
3.3.2. Kaplan–Meier analysis
Patients with detectable levels of KLK3 had a signifi-
cantly shorter PFS compared to patients without
KLK3 detection, median 201 vs 501 days
(P = 0.00054). Patients with expression levels of miR-
375 above cutoff showed shorter PFS compared to
patients with miR-375 levels below cutoff, although
not statistically significant, median 352 vs 456 days
(P = 0.076). Figure 1A,B shows the survival curves.
3.4. Abiraterone exposure
The abiraterone trough concentration (Ctrough) was
measured in 52 patients. Pharmacokinetic assessment
in one patient failed due to errors made in blood sam-
ple collection. The mean calculated abiraterone Ctrough
was 14.5 ngmL1 with a range of 3.4–92.1 ngmL1.
The intra- and interpatient variability was 30.2% and
49.5%, respectively. In total, 10 patients had a mean
Ctrough level below the threshold of 8.4 ngmL1. In
univariable Cox regression analysis a mean Ctrough
level ≥ 8.4 ngmL1 was not related to PFS (HR 0.85;
95% CI 0.37–1.95, P = 0.70; Table 3).
3.5. Longitudinal follow-up of treatment
response using AR-V7, KLK3, and miR-375
During treatment, 13 patients stopped AA-P therapy
due to progression within 6 months (early progression,
median time to PFS of 3 months). Expression levels of
AR-V7, KLK3, and miR-375 over time in patients with
early progression were compared with patients who
responded to treatment (stable disease or partial
response, median PFS follow-up of 15 months).
At baseline, six patients were AR-V7 positive, of
which five patients responded to treatment (stable dis-
ease or partial response). During treatment, AR-V7
positivity dropped in all six patients to undetectable
levels. Expression levels of KLK3 are higher and more
frequent detectable in patients with early progression
compared with responders. Under treatment, expres-
sion levels of KLK3 decreased. For patients who
responded to AA-P treatment, KLK3 was not detect-
able in any patient at 3 months, where in patients with
early progression KLK3 was still detected in five
patients (55.6%) (Fig. 2A).
At baseline, 17 patients were KLK3 positive of which
seven patients responded to treatment (stable disease or
partial response) and 10 patients had early progression.
At 6 months, only three patients were KLK3 positive
(Fig. 2A and Table 2). This drop is due to the fact that
8 KLK3-positive patients at baseline dropped out before
evaluation at 6 months due to early progression. Fur-
thermore, in seven patients KLK3 levels dropped to
undetectable levels after 3 months, which is reflecting
treatment response. One patient became KLK3 positive
at 6 months during treatment. Levels of miR-375
showed an overall decrease after start of AA-P therapy
regardless of response. Patients with early progression
had higher levels of miR-375 compared with respon-
ders, especially at baseline. However, no clear pattern in
changes in miR-375 levels over time was observed
Table 3. Cox regression analysis in relation to PFS.
Univariable Multivariable (N = 51a)
HR (95%CI) P-value HR (95%CI) P-value
AR-V7 positive 1.37 (0.53–3.57) 0.52 – –
KLK3 positive 3.16 (1.59–6.27) < 0.0001 5.07 (1.81–14.18) 0.0020
miR-375 > cutoff 1.78 (0.93–3.41) 0.08 1.10 (0.49–2.48) 0.81
miR-3687 > cutoff 2.41 (0.73–7.99) 0.15 – –
NAALADL2-AS2 > cutoff 0.60 (0.31–1.15) 0.14 – –
Abiraterone Ctrough > 8.4 ngmL1 0.85 (0.37–1.95) 0.70 – –
Pretreatment according to
CHAARTED/STAMPEDE
0.91 (0.46–1.80) 0.78 – –
Visceral metastasis 0.87 (0.39–1.90) 0.72 – –
Lymph node metastasis 1.86 (0.94–3.65) 0.07 2.57 (1.20–5.50) 0.0149
LDH > ULN 1.53 (0.79–2.96) 0.21 1.77 (0.77–4.05) 0.18
Hb ≤ LLN 1.55 (0.78–3.10) 0.21 1.44 (0.63–3.33) 0.39
PSA > 39.5 ngmL1 2.32 (1.21–4.44) 0.01 1.54 (0.70–3.38) 0.29
≥ 10 bone metastases 2.39 (1.23–4.64) 0.0098 1.62 (0.72–3.62) 0.24
a
Two observations deleted due to missing covariables.
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between the responders and patients with early progres-
sion (Fig. 2B).
4. Discussion
In this study, the prognostic value of KLK3 mRNA
and other novel circulating RNAs in first-line mCRPC
patients starting AA-P was studied. Furthermore, the
effect of abiraterone exposure on treatment outcome
was evaluated. Our study confirmed that detectable
levels of KLK3 at baseline appear to be prognostic for
shorter PFS. Furthermore, circulating KLK3 mRNA
levels outperform all other investigated clinical prog-
nostic biomarkers.
To the best of our knowledge, this is the first
prospective clinical trial confirming KLK3 as a prog-
nostic biomarker for PFS. Previous work revealed that
KLK2/3 mRNA detection in whole blood by RT–PCR
is highly concordant with CTCs detected by the Cell-
Search system [36]. Danila et al. [9] investigated
whether the CTCs detected with the CellSearch and
AdnaTest assay or the direct detection of tumor
mRNA with a ddPCR method were the best biomar-
ker for OS. The ddPCR and AdnaTest had higher
detection rates compared with the CellSearch system,
and therefore were superior to the CellSearch system.
Because KLK3 mRNA detection appeared to be the
most relevant marker for a positive result by the
AdnaTest and ddPCR, detection of KLK3 mRNA in
whole blood can be used as a surrogate marker for
CTC counts [9]. Since CTC isolation is technically and
logistically challenging, the clinical utility of CTC enu-
meration in this disease setting is minimal. We showed
that our RT–PCR method for KLK3 detection in
whole blood collected in PAXgene tubes is a sensitive
method and could be used in first-line patients. The
method requires minimal sample pretreatment and
therefore can easily be implemented into clinical prac-
tice. KLK3 mRNA detection in early disease setting,
but presumably also in patients with more advanced
disease, might therefore be an easier to measure bio-
marker compared to CTC detection.
By longitudinally follow-up of KLK3 mRNA levels,
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Fig. 1. KM curves for PFS. (A) PFS according to KLK3 detection at baseline: nondetectable vs detectable as cutoff value in abiraterone-
treated patients. (B) PFS according to miR-375 expression levels at baseline: < 2.16 vs ≥ 2.16 relative to healthy controls as cutoff value in
abiraterone-treated patients. P-values are calculated by log-rank test.
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treatment response. Previous work in CRPC patients
treated with docetaxel revealed that KLK3 levels in
patients responding to docetaxel were decreased [7]. In
our study, we found similar results, all patients
responding to AA-P (median PFS follow-up of
15 months) had undetectable KLK3 after 3 months of
treatment. Because KLK3 is the transcript encoding
for PSA, one might think that KLK3 would be related
to PSA levels. However, in our multivariable Cox
regression analysis serum PSA was not prognostic for
survival. This emphasizes the additional value of
KLK3 mRNA detection over serum PSA measure-
ment. Although serum PSA is clinically used to moni-
tor treatment response, serum PSA levels may not
reflect the status of the disease accurately [37]. CTC
enumeration has been incorporated by the PCWG3 as
a clinical endpoint in trials for treatment response [38].
Since KLK3 mRNA detection likely reflects CTC bur-
den, KLK3 detection may alternatively be used to
assess treatment response. This hypothesis should be
confirmed in a larger well-annotated patient cohort
with time to progression data and blood collection for
translational RNA studies.
Another potentially promising RNA biomarker is
miR-375. However, in multivariable analysis and KM
analysis, no statistically significant effect was seen in
our cohort which might be due to our limited number
of patients. Several previous studies showed that
higher miR-375 levels at baseline are related to shorter
survival [39,13]. Therefore, miR-375 is potentially
promising and should be considered for preclinical
functionality testing and future clinical validation.
MiR-3687 and NAALADL2-AS2 were also upregu-
lated in PCa patients compared with healthy controls.
However, both biomarkers failed to be related to PFS.
In our previous cohort of first-line mCRPC patients
treated with enzalutamide, high levels of miR-3687
and low levels of NAALADL2-AS2 were significantly
prognostic of shorter PFS. Since the functionality of
miR-3687 and NAALADL2-AS2 in PCa is currently
not clear, preclinical functionality testing is required
before these results can be interpreted. Future clinical
validation of these biomarkers in a larger independent
cohort is needed.
In our study, AR-V7 RNA levels were not prognos-
tic for survival. Our study included only first-line AA-
P patients. Six out of 53 patients (11.3%) were AR-V7
positive with copy numbers just above the lower limit
of quantification, while AR levels were not distinctive
from healthy volunteers. A previous study showed that
only 3% of first-line patients were AR-V7 positive [23].
In our study, a whole blood AR-V7 test is used, while
most studies have been performed with AR-V7 detec-
tion in CTCs. AR-V7 detection in whole blood might
Fig. 2. Boxplots of KLK3 (A) and miR-375 (B) expression levels over time. Left panel shows patients who progressed early (< 6 months)
after start of AA-P therapy, right panel shows patients with stable disease / responders to AA-P therapy (progression ≥ 6 months). The
bottom and top of the box are the 25th and 75th percentiles, and the line inside the box is the median.
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have a lower sensitivity compared with CTC-based
AR-V7 detection. On the other hand, many first-line
patients are CTCs negative, and therefore, CTC-based
AR-V7 detection is not useful. It has been shown that
whole blood AR-V7 positivity is correlated with CTC
counts and that patients with undetectable CTC levels
still can be AR-V7 positive when using whole blood
[40]. Therefore, the predictive value of AR-V7 in whole
blood might only be clinically relevant for higher copy
numbers of AR-V7 which can be detected at later
stages of treatment. Future research should compare
CTC-based and whole blood-based AR-V7 detection,
and determine a clinically relevant threshold for AR-
V7 detection in whole blood. Next to the biomarkers,
we studied the effect of drug exposure on PFS. It has
been suggested that underexposure of abiraterone
(Ctrough level < 8.4 ngmL1) is related to shorter PFS
[26,27]. The beneficial effect of higher abiraterone
exposure levels could not be confirmed in this study
for chemotherapy na€ıve patients treated with AA-P.
This could be due to our study cohort of only first-line
patients. Xu et al. [41] found that the effective concen-
tration levels of abiraterone in chemotherapy-na€ıve
patients were lower compared with postchemotherapy
patients. The previously defined threshold has been
established in a mixed cohort of chemotherapy-na€ıve
and chemotherapy-pretreated patients. Future research
is necessary to investigate the threshold for abiraterone
in chemotherapy-na€ıve patients treated with AA-P.
In our study, besides KLK3 mRNA, the prognostic
value of the other biomarkers and drug exposure could
not be confirmed. Since the prostate landscape is
changing, and the indication for drugs such as AA-P
has broadened from the castration-resistant to the hor-
mone-sensitive setting, it is important to study the
value of biomarkers and drug exposure in a clear sub-
set of patients. In this light, we set up a well-defined
cohort of only first-line mCRPC patients treated with
AA-P. This explains the lower expression levels of
most RNAs compared with previous studies and
underscores the need to investigate the added value of
biomarkers in well-defined stage of disease.
Although the biomarker research field is growing,
there remains a large gap between biomarker discovery
and clinical validation. Therefore, prospective clinical
validation of biomarkers is needed. Our study is a step
forward in biomarker validation, providing valuable
information in an independent group of patients in a
prospective study design about the clinical validation
of KLK3 mRNA and absent value of the other investi-
gated biomarkers in identifying patients who will bene-
fit shorter from AA-P therapy. A strength of our
study is that we have used healthy controls to make
sure that the biomarkers we measured are related to
prostate cancer. Only biomarkers which were upregu-
lated in CRPC patients compared with healthy con-
trols are selected. Therefore, our working hypothesis is
that the identified whole blood RNA biomarkers are
reflecting disease burden. Expression levels of many of
the circulating RNAs in our cohort were not distinc-
tive from expression levels in healthy controls. This
highlights the need of incorporating a control cohort
to identify biomarkers that are specifically upregulated
in patients with mCRPC. Results of biomarker studies
without healthy volunteers should therefore be inter-
preted with more caution.
5. Conclusions
Our study confirmed KLK3 mRNA as an independent
prognostic marker for PFS in mCRPC patients receiv-
ing first-line AA-P treatment. Detection of whole
blood KLK3 could be easily incorporated into clinical
practice. KLK3 detection over time may be a potential
biomarker to monitor treatment response or progres-
sion, but prospective clinical validation is needed.
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